SeaStar Medical (ICU) Stock: Buy, Sell, or Hold?
ICU - SeaStar Medical Holding Corporation Common Stock
$4.69
0.94 (25.07%)
▲
5d:
+37.13%
30d:
+62.85%
90d:
-1.47%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When ICU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ICU is 27.1% above its trading range ($3.69). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ICU is 27.1% above its trading range ($3.69). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ICU is currently trading at $4.69, which is considered extended relative to its 30-day fair value range of $2.93 to $3.69.
Technical Outlook: Technically, ICU is in a downtrend. The price is approaching resistance at $4.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 25.1% recently.
Market Sentiment: ICU scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+113.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ICU is in a downtrend. The price is approaching resistance at $4.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 25.1% recently.
Market Sentiment: ICU scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+113.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.93 -
$3.69
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+27.1% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+25.1%)
- BULLISH: Trading 113.2% below Wall St target ($10.00)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.93 -
$3.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.22
Resistance Level
$4.80
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.01
Wall Street Target
$10.00
(+113.2%)
Revenue Growth (YoY)
82.0%
Share & Embed Analysis
Last updated: October 03, 2026 8:31 PM ET
Data refreshes hourly during market hours. Next update: 9:31 PM
Data refreshes hourly during market hours. Next update: 9:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
